Last reviewed · How we verify
Imeron (IOMEPROL)
Iomeprol (Imeron) is a marketed contrast agent used in medical imaging to enhance visualization of organs such as the kidneys. Its key strength lies in its ability to provide clear images, which aids in accurate diagnosis and monitoring. The primary risk is the upcoming key patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | IOMEPROL |
|---|---|
| Sponsor | Bracco |
| Drug class | Radiographic Contrast Agent [EPC] |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 2024 |
Approved indications
Common side effects
- Feeling hot
- Headache
- Nausea
- Chest pain
- Back pain
- Vomiting
Serious adverse events
- Respiratory arrest
- Ventricular fibrillation
- Hypertensive crisis
- Coronary arteriospasm
- Congestive cardiac failure
- Acute kidney injury
- Pulmonary edema
- Bronchospasm
- Cerebrovascular disorder
- Esophageal varices hemorrhage
Key clinical trials
- Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT Examinations (NA)
- Interest of Intravenous Cholangiography With Indocyanine Green in the Context of Laparoscopic Cholecystectomy for Grade 1 and 2 Acute Gallstone Cholecystitis (NA)
- Comparison of Low-dose Spiral Breast CT With MRI in Major Indications of MRI for Breast Diagnostics (NA)
- Comparison of Spectral Photon Counting CT (SPCCT) With Dual Energy CT (DECT) and Magnetic Resonance Imaging (MRI) for Plaque and Lumen Carotid Arteries Evaluation (NA)
- Pericapsular Nerve Group Block: An Imaging Study for Determination of the Spread of the Injectate Using 3-D CT Scan (NA)
- Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT (NA)
- Comparison of Icg's Route of Administration During Laparoscopic Cholecystectomy (NA)
- PErirenal Adipose Tissue and RenaL Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imeron CI brief — competitive landscape report
- Imeron updates RSS · CI watch RSS